Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

CDA deficiency as a possible culprit for life-threatening toxicities after cytarabine plus 6-mercaptopurine therapy: pharmacogenetic investigations.

Ciccolini J, Evrard A, M'Batchi L, Pourroy B, Mercier C, Iliadis A, Lacarelle B, Verschuur A, Ouafik L, André N.

Pharmacogenomics. 2012 Mar;13(4):393-7. doi: 10.2217/pgs.11.175.

PMID:
22379997
2.

Recipient/donor contradictory genotypes with impact on drug pharmacogenetics after liver transplant: a deadly gift?

Serdjebi C, Ciccolini J, Fina F, Delarue A, Verschuur A, Lacarelle B, Ouafik L, André N.

Pharmacogenet Genomics. 2014 Oct;24(10):527-9. doi: 10.1097/FPC.0000000000000076.

PMID:
25003625
3.

Variability in transport and biotransformation of cytarabine is associated with its toxicity in peripheral blood mononuclear cells.

Parmar S, Seeringer A, Denich D, Gärtner F, Pitterle K, Syrovets T, Ohmle B, Stingl JC.

Pharmacogenomics. 2011 Apr;12(4):503-14. doi: 10.2217/pgs.10.200.

PMID:
21521023
4.

Toxic death case in a patient undergoing gemcitabine-based chemotherapy in relation with cytidine deaminase downregulation.

Mercier C, Raynal C, Dahan L, Ortiz A, Evrard A, Dupuis C, Blesius A, Duluc M, Franceschini F, Giacometti S, Salas S, Milano G, Favre R, Seitz JF, Ciccolini J.

Pharmacogenet Genomics. 2007 Oct;17(10):841-4.

PMID:
17885621
5.

Cytidine deaminase genetic variants influence RNA expression and cytarabine cytotoxicity in acute myeloid leukemia.

Abraham A, Varatharajan S, Abbas S, Zhang W, Shaji RV, Ahmed R, Abraham A, George B, Srivastava A, Chandy M, Mathews V, Balasubramanian P.

Pharmacogenomics. 2012 Feb;13(3):269-82. doi: 10.2217/pgs.11.149.

PMID:
22304580
6.

Early severe toxicities after capecitabine intake: possible implication of a cytidine deaminase extensive metabolizer profile.

Mercier C, Dupuis C, Blesius A, Fanciullino R, Yang CG, Padovani L, Giacometti S, Frances N, Iliadis A, Duffaud F, Ciccolini J.

Cancer Chemother Pharmacol. 2009 May;63(6):1177-80. doi: 10.1007/s00280-008-0889-1.

PMID:
19107485
7.

Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus.

Relling MV, Hancock ML, Rivera GK, Sandlund JT, Ribeiro RC, Krynetski EY, Pui CH, Evans WE.

J Natl Cancer Inst. 1999 Dec 1;91(23):2001-8.

8.

Rapid deaminator status is associated with poor clinical outcome in pancreatic cancer patients treated with a gemcitabine-based regimen.

Serdjebi C, Seitz JF, Ciccolini J, Duluc M, Norguet E, Fina F, Lacarelle B, Ouafik L, Dahan L.

Pharmacogenomics. 2013 Jul;14(9):1047-51. doi: 10.2217/pgs.13.93.

PMID:
23837479
9.

Effect of genetic alterations of cytarabine- metabolizing enzymes in childhood acute lymphoblastic leukemia.

Banklau C, Jindadamrongwech S, Sawangpanich R, Apibal S, Hongeng S, Paisooksantivatana K, Pakakasama S.

Hematol Oncol Stem Cell Ther. 2010;3(3):103-8.

10.

Lethal toxicity after administration of azacytidine: implication of the cytidine deaminase-deficiency syndrome.

Fanciullino R, Mercier C, Serdjebi C, Berda Y, Fina F, Ouafik L, Lacarelle B, Ciccolini J, Costello R.

Pharmacogenet Genomics. 2015 Jun;25(6):317-21. doi: 10.1097/FPC.0000000000000139.

PMID:
25850965
11.

High incidence of severe neutropenia after gemcitabine-based chemotherapy in Chinese cancer patients with CDA 79A>C mutation.

Xu J, Zhou Y, Zhang J, Chen Y, Zhuang R, Liu T, Cai W.

Clin Chim Acta. 2012 Aug 16;413(15-16):1284-7. doi: 10.1016/j.cca.2012.04.018.

PMID:
22546611
12.

[Study on the relationship between human cytidine deaminase gene polymorphisms and Ara-C sensitivity].

Chen XW, Yue LJ, Li CR, Li CG, Shi HS, Zhang M.

Zhonghua Xue Ye Xue Za Zhi. 2008 Jul;29(7):459-63. Chinese.

PMID:
19035178
13.

Cytidine deaminase residual activity in serum is a predictive marker of early severe toxicities in adults after gemcitabine-based chemotherapies.

Ciccolini J, Dahan L, André N, Evrard A, Duluc M, Blesius A, Yang C, Giacometti S, Brunet C, Raynal C, Ortiz A, Frances N, Iliadis A, Duffaud F, Seitz JF, Mercier C.

J Clin Oncol. 2010 Jan 1;28(1):160-5. doi: 10.1200/JCO.2009.24.4491.

PMID:
19933910
14.
15.

Pharmacogenomic studies of the anticancer and immunosuppressive thiopurines mercaptopurine and azathioprine.

Hawwa AF, Millership JS, Collier PS, Vandenbroeck K, McCarthy A, Dempsey S, Cairns C, Collins J, Rodgers C, McElnay JC.

Br J Clin Pharmacol. 2008 Oct;66(4):517-28. doi: 10.1111/j.1365-2125.2008.03248.x.

16.

High-resolution melting analysis of sequence variations in the cytidine deaminase gene (CDA) in patients with cancer treated with gemcitabine.

Raynal C, Ciccolini J, Mercier C, Boyer JC, Polge A, Lallemant B, Mouzat K, Lumbroso S, Brouillet JP, Evrard A.

Ther Drug Monit. 2010 Feb;32(1):53-60. doi: 10.1097/FTD.0b013e3181c77c1b.

PMID:
20010457
17.
18.

Pharmacokinetics of gemcitabine in Japanese cancer patients: the impact of a cytidine deaminase polymorphism.

Sugiyama E, Kaniwa N, Kim SR, Kikura-Hanajiri R, Hasegawa R, Maekawa K, Saito Y, Ozawa S, Sawada J, Kamatani N, Furuse J, Ishii H, Yoshida T, Ueno H, Okusaka T, Saijo N.

J Clin Oncol. 2007 Jan 1;25(1):32-42.

PMID:
17194903
19.

Yin and yang of cytidine deaminase roles in clinical response to azacitidine in the elderly: a pharmacogenetics tale.

Fanciullino R, Mercier C, Serdjebi C, Venton G, Colle J, Fina F, Ouafik L, Lacarelle B, Ciccolini J, Costello R.

Pharmacogenomics. 2015 Nov;16(17):1907-12. doi: 10.2217/pgs.15.135.

PMID:
26556583
20.

Determination of common genetic variants in cytidine deaminase (CDA) gene in Indian ethnic population.

Iyer SN, Ankala A, Singhal RS, Hegde MR.

Gene. 2013 Jul 15;524(1):35-9. doi: 10.1016/j.gene.2013.04.015.

PMID:
23612254
Items per page

Supplemental Content

Support Center